TY - JOUR
T1 - The use of glutathione to reduce oxidative stress status and its potential for modifying the extracellular matrix organization in cleft lip
AU - Li, Rong
AU - Huang, Chen
AU - Ho, Jeff Cheuk Hin
AU - Leung, Cherry Chi Tim
AU - Kong, Richard Yuen Chong
AU - Li, Yu
AU - Liang, Xiao
AU - Lai, Keng Po
AU - Tse, William Ka Fai
N1 - Funding Information:
This study was supported by the National Natural Science Foundation of China (No. 81560134 ) and the National Natural Science Foundation of Guangxi (No. 2019GXNSFBA185015 ). The pathology works in WKF Tse Laboratory were partially supported by the Japan Society for the Promotion of Science Bilateral Open Partnership Joint Research Project AJ179064; the joint research program of the Institute for Molecular and Cellular Regulation, Gunma University , Japan (18003); and the National Institute of Basic Biology Collaborative Research Program, Japan (19–307).
Publisher Copyright:
© 2021 Elsevier Inc.
PY - 2021/2/20
Y1 - 2021/2/20
N2 - Objective: Cleft lip (CL) is a common congenital anomaly that can be syndromic or non-syndromic. It can be triggered by the mutation of gene or environmental factors. The incidence of CL is about 1 out of 700 live births. Facial development is a complex process, and there is no existing therapy to prevent the disease development. One of the characteristics in this facial malformation is the increased presence of reactive oxygen species (ROS). In this study, we hypothesize that the antioxidant glutathione (GSH) could help to attenuate the oxidative stress in this disease. Methods: Bioinformatics network pharmacology was applied to determine pharmacological targets and molecular mechanisms of GSH treatment for CL. Moreover, RNA-sequencing of the POLR1C knockdown osteoblast CL model was applied to validate the in silico data of using GSH in CL. Results: Twenty-two core targets of GSH and CL were identified via various bioinformatics tools. The GO and KEGG analysis indicated that GSH could modulate two major families (matrix metalloproteinase and integrins), which are related to extracellular matrix modification and composition for facial development in CL. The findings from POLR1C knockdown model further supported the rescue response of GSH in CL. Conclusions: The study uncovered the possible pharmacological mechanism of GSH for treating CL. The data helps research group to focus on the specific pathways for understanding the biological action of GSH for treating the CL in the future.
AB - Objective: Cleft lip (CL) is a common congenital anomaly that can be syndromic or non-syndromic. It can be triggered by the mutation of gene or environmental factors. The incidence of CL is about 1 out of 700 live births. Facial development is a complex process, and there is no existing therapy to prevent the disease development. One of the characteristics in this facial malformation is the increased presence of reactive oxygen species (ROS). In this study, we hypothesize that the antioxidant glutathione (GSH) could help to attenuate the oxidative stress in this disease. Methods: Bioinformatics network pharmacology was applied to determine pharmacological targets and molecular mechanisms of GSH treatment for CL. Moreover, RNA-sequencing of the POLR1C knockdown osteoblast CL model was applied to validate the in silico data of using GSH in CL. Results: Twenty-two core targets of GSH and CL were identified via various bioinformatics tools. The GO and KEGG analysis indicated that GSH could modulate two major families (matrix metalloproteinase and integrins), which are related to extracellular matrix modification and composition for facial development in CL. The findings from POLR1C knockdown model further supported the rescue response of GSH in CL. Conclusions: The study uncovered the possible pharmacological mechanism of GSH for treating CL. The data helps research group to focus on the specific pathways for understanding the biological action of GSH for treating the CL in the future.
UR - http://www.scopus.com/inward/record.url?scp=85099387720&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85099387720&partnerID=8YFLogxK
U2 - 10.1016/j.freeradbiomed.2020.12.455
DO - 10.1016/j.freeradbiomed.2020.12.455
M3 - Article
C2 - 33422675
AN - SCOPUS:85099387720
SN - 0891-5849
VL - 164
SP - 130
EP - 138
JO - Free Radical Biology and Medicine
JF - Free Radical Biology and Medicine
ER -